Triple versus dual antiplatelet therapy after coronary stenting

Impact on stent thrombosis

Seung Whan Lee, Seong Wook Park, Myeongki Hong, Young Hak Kim, Bong Ki Lee, Jong Min Song, Ki Hoon Han, Cheol Whan Lee, Duk Hyun Kang, Jae Kwan Song, Jae Joong Kim, Seung Jung Park

Research output: Contribution to journalArticle

198 Citations (Scopus)

Abstract

OBJECTIVES: We evaluated safety and efficacy of triple antiplatelet therapy with aspirin, clopidogrel, or ticlopidine and cilostazol after coronary stenting. BACKGROUND: Triple antiplatelet therapy might have beneficial effect to prevent thrombotic complications in patients undergoing coronary stenting. METHODS: Patients undergoing successful coronary stenting were divided into dual antiplatelet therapy (aspirin plus clopidogrel or ticlopidine, group I, n = 1,597) and triple antiplatelet therapy (aspirin plus clopidogrel or ticlopidine plus cilostazol, group II, n = 1,415) groups. The primary end point included death, myocardial infarction, target lesion revascularization, or stent thrombosis within 30 days. The secondary end point was side effects of study drugs, including major bleeding, vascular complication, hepatic dysfunction, and hematological complications. RESULTS: Multi-vessel stenting and the use of long stents were more prevalent in group II than in group I. The primary end point was 0.8% in group I and 0.3% in group II (p = 0.085). Stent thrombosis within 30 days was significantly lower in group II (n = 1, 0.1%) than in group I (n = 9, 0.5%; p = 0.024). The independent predictors of stent thrombosis were primary stenting (odds ratio [OR] 7.9, 95% confidence interval [CI] 2.0 to 30.8, p = 0.003) and triple therapy (OR 0.12, 95% CI 0.015 to 0.98, p = 0.048). The overall adverse drug effects, including major bleeding, neutropenia, and thrombocytopenia, were no different between two groups (1.8% vs. 2.6%, p = 0.104). CONCLUSIONS: Compared with the dual antiplatelet regimen, triple antiplatelet therapy seemed to be more effective in preventing thrombotic complications after stenting without an increased risk of side effects. Triple antiplatelet therapy might be safely applied in patients or lesions with a high risk of stent thrombosis.

Original languageEnglish
Pages (from-to)1833-1837
Number of pages5
JournalJournal of the American College of Cardiology
Volume46
Issue number10
DOIs
Publication statusPublished - 2005 Nov 15

Fingerprint

clopidogrel
Stents
Thrombosis
Ticlopidine
Aspirin
Therapeutics
Odds Ratio
Confidence Intervals
Hemorrhage
Neutropenia
Drug-Related Side Effects and Adverse Reactions
Thrombocytopenia
Blood Vessels
Myocardial Infarction
Safety
Liver
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Seung Whan ; Park, Seong Wook ; Hong, Myeongki ; Kim, Young Hak ; Lee, Bong Ki ; Song, Jong Min ; Han, Ki Hoon ; Lee, Cheol Whan ; Kang, Duk Hyun ; Song, Jae Kwan ; Kim, Jae Joong ; Park, Seung Jung. / Triple versus dual antiplatelet therapy after coronary stenting : Impact on stent thrombosis. In: Journal of the American College of Cardiology. 2005 ; Vol. 46, No. 10. pp. 1833-1837.
@article{1b1fd706b30b476598e6cb81a35cf46b,
title = "Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis",
abstract = "OBJECTIVES: We evaluated safety and efficacy of triple antiplatelet therapy with aspirin, clopidogrel, or ticlopidine and cilostazol after coronary stenting. BACKGROUND: Triple antiplatelet therapy might have beneficial effect to prevent thrombotic complications in patients undergoing coronary stenting. METHODS: Patients undergoing successful coronary stenting were divided into dual antiplatelet therapy (aspirin plus clopidogrel or ticlopidine, group I, n = 1,597) and triple antiplatelet therapy (aspirin plus clopidogrel or ticlopidine plus cilostazol, group II, n = 1,415) groups. The primary end point included death, myocardial infarction, target lesion revascularization, or stent thrombosis within 30 days. The secondary end point was side effects of study drugs, including major bleeding, vascular complication, hepatic dysfunction, and hematological complications. RESULTS: Multi-vessel stenting and the use of long stents were more prevalent in group II than in group I. The primary end point was 0.8{\%} in group I and 0.3{\%} in group II (p = 0.085). Stent thrombosis within 30 days was significantly lower in group II (n = 1, 0.1{\%}) than in group I (n = 9, 0.5{\%}; p = 0.024). The independent predictors of stent thrombosis were primary stenting (odds ratio [OR] 7.9, 95{\%} confidence interval [CI] 2.0 to 30.8, p = 0.003) and triple therapy (OR 0.12, 95{\%} CI 0.015 to 0.98, p = 0.048). The overall adverse drug effects, including major bleeding, neutropenia, and thrombocytopenia, were no different between two groups (1.8{\%} vs. 2.6{\%}, p = 0.104). CONCLUSIONS: Compared with the dual antiplatelet regimen, triple antiplatelet therapy seemed to be more effective in preventing thrombotic complications after stenting without an increased risk of side effects. Triple antiplatelet therapy might be safely applied in patients or lesions with a high risk of stent thrombosis.",
author = "Lee, {Seung Whan} and Park, {Seong Wook} and Myeongki Hong and Kim, {Young Hak} and Lee, {Bong Ki} and Song, {Jong Min} and Han, {Ki Hoon} and Lee, {Cheol Whan} and Kang, {Duk Hyun} and Song, {Jae Kwan} and Kim, {Jae Joong} and Park, {Seung Jung}",
year = "2005",
month = "11",
day = "15",
doi = "10.1016/j.jacc.2005.07.048",
language = "English",
volume = "46",
pages = "1833--1837",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "10",

}

Lee, SW, Park, SW, Hong, M, Kim, YH, Lee, BK, Song, JM, Han, KH, Lee, CW, Kang, DH, Song, JK, Kim, JJ & Park, SJ 2005, 'Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis', Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1833-1837. https://doi.org/10.1016/j.jacc.2005.07.048

Triple versus dual antiplatelet therapy after coronary stenting : Impact on stent thrombosis. / Lee, Seung Whan; Park, Seong Wook; Hong, Myeongki; Kim, Young Hak; Lee, Bong Ki; Song, Jong Min; Han, Ki Hoon; Lee, Cheol Whan; Kang, Duk Hyun; Song, Jae Kwan; Kim, Jae Joong; Park, Seung Jung.

In: Journal of the American College of Cardiology, Vol. 46, No. 10, 15.11.2005, p. 1833-1837.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Triple versus dual antiplatelet therapy after coronary stenting

T2 - Impact on stent thrombosis

AU - Lee, Seung Whan

AU - Park, Seong Wook

AU - Hong, Myeongki

AU - Kim, Young Hak

AU - Lee, Bong Ki

AU - Song, Jong Min

AU - Han, Ki Hoon

AU - Lee, Cheol Whan

AU - Kang, Duk Hyun

AU - Song, Jae Kwan

AU - Kim, Jae Joong

AU - Park, Seung Jung

PY - 2005/11/15

Y1 - 2005/11/15

N2 - OBJECTIVES: We evaluated safety and efficacy of triple antiplatelet therapy with aspirin, clopidogrel, or ticlopidine and cilostazol after coronary stenting. BACKGROUND: Triple antiplatelet therapy might have beneficial effect to prevent thrombotic complications in patients undergoing coronary stenting. METHODS: Patients undergoing successful coronary stenting were divided into dual antiplatelet therapy (aspirin plus clopidogrel or ticlopidine, group I, n = 1,597) and triple antiplatelet therapy (aspirin plus clopidogrel or ticlopidine plus cilostazol, group II, n = 1,415) groups. The primary end point included death, myocardial infarction, target lesion revascularization, or stent thrombosis within 30 days. The secondary end point was side effects of study drugs, including major bleeding, vascular complication, hepatic dysfunction, and hematological complications. RESULTS: Multi-vessel stenting and the use of long stents were more prevalent in group II than in group I. The primary end point was 0.8% in group I and 0.3% in group II (p = 0.085). Stent thrombosis within 30 days was significantly lower in group II (n = 1, 0.1%) than in group I (n = 9, 0.5%; p = 0.024). The independent predictors of stent thrombosis were primary stenting (odds ratio [OR] 7.9, 95% confidence interval [CI] 2.0 to 30.8, p = 0.003) and triple therapy (OR 0.12, 95% CI 0.015 to 0.98, p = 0.048). The overall adverse drug effects, including major bleeding, neutropenia, and thrombocytopenia, were no different between two groups (1.8% vs. 2.6%, p = 0.104). CONCLUSIONS: Compared with the dual antiplatelet regimen, triple antiplatelet therapy seemed to be more effective in preventing thrombotic complications after stenting without an increased risk of side effects. Triple antiplatelet therapy might be safely applied in patients or lesions with a high risk of stent thrombosis.

AB - OBJECTIVES: We evaluated safety and efficacy of triple antiplatelet therapy with aspirin, clopidogrel, or ticlopidine and cilostazol after coronary stenting. BACKGROUND: Triple antiplatelet therapy might have beneficial effect to prevent thrombotic complications in patients undergoing coronary stenting. METHODS: Patients undergoing successful coronary stenting were divided into dual antiplatelet therapy (aspirin plus clopidogrel or ticlopidine, group I, n = 1,597) and triple antiplatelet therapy (aspirin plus clopidogrel or ticlopidine plus cilostazol, group II, n = 1,415) groups. The primary end point included death, myocardial infarction, target lesion revascularization, or stent thrombosis within 30 days. The secondary end point was side effects of study drugs, including major bleeding, vascular complication, hepatic dysfunction, and hematological complications. RESULTS: Multi-vessel stenting and the use of long stents were more prevalent in group II than in group I. The primary end point was 0.8% in group I and 0.3% in group II (p = 0.085). Stent thrombosis within 30 days was significantly lower in group II (n = 1, 0.1%) than in group I (n = 9, 0.5%; p = 0.024). The independent predictors of stent thrombosis were primary stenting (odds ratio [OR] 7.9, 95% confidence interval [CI] 2.0 to 30.8, p = 0.003) and triple therapy (OR 0.12, 95% CI 0.015 to 0.98, p = 0.048). The overall adverse drug effects, including major bleeding, neutropenia, and thrombocytopenia, were no different between two groups (1.8% vs. 2.6%, p = 0.104). CONCLUSIONS: Compared with the dual antiplatelet regimen, triple antiplatelet therapy seemed to be more effective in preventing thrombotic complications after stenting without an increased risk of side effects. Triple antiplatelet therapy might be safely applied in patients or lesions with a high risk of stent thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=27644555633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644555633&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2005.07.048

DO - 10.1016/j.jacc.2005.07.048

M3 - Article

VL - 46

SP - 1833

EP - 1837

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 10

ER -